Adhera Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ATRX Over the counter 2834 https://adherathera.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adhera Therapeutics Inc

Manufacturing Commences on Adhera’s MLR-1019 for Phase 2a Clinical Trial Treating Parkinson’s Disease - Oct 15th, 2021 2:21 pm
Adhera Receives European Patent Covering MLR-1019 and Derivatives for Treating Dyskinesias - Oct 4th, 2021 1:15 pm
Adhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes Drugs - Sep 13th, 2021 2:28 pm
Adhera Therapeutics Appoints Dr. Andrew Reaume to Board of Directors - Sep 9th, 2021 1:05 pm
Adhera Therapeutics Signs Exclusive License Agreement with Melior Pharmaceuticals I for New Type 1 Diabetes Drug Candidate - Aug 24th, 2021 1:20 pm
Adhera Signs Definitive License Agreement with Melior Pharmaceuticals II for New Parkinson’s Disease Drug Candidate - Jul 29th, 2021 1:00 pm
Adhera Therapeutics Signs Letter of Intent with Melior Pharmaceuticals II to Acquire a New Class of Drug for Parkinson’s Disease - Jun 7th, 2021 12:45 pm
Adhera Therapeutics Appoints Trond K. Waerness to Board of Directors - Apr 23rd, 2021 1:00 pm